Report Information More information from: https ://www.wis eguyreports .com/reports /495857
Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016 Report / Search Code: WGR495857
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016’, provides in depth analys is on Melanocortin Receptor 4 (MC4-R or MC4R) targeted pipeline therapeutics . The report provides comprehens ive information on the Melanocortin Receptor 4 (MC4-R or MC4R), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Melanocortin Receptor 4 (MC4-R or MC4R) - The report reviews Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Melanocortin Receptor 4 (MC4R or MC4R) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4-R or MC4R) - Identify the us e of drugs for target identification and drug repurpos ing
- Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Melanocortin Receptor 4 (MC4-R or MC4R) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Melanocortin Receptor 4 (MC4-R or MC4R) Overview 7 Therapeutics Development 8 Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Stage of Development 8 Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Therapy Area 9 Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Indication 10 Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Companies 14 Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Univers ities /Ins titutes 16 Melanocortin Receptor 4 (MC4-R or MC4R) - Therapeutics As s es s ment 18 As s es s ment by Monotherapy/Combination Products 18 As s es s ment by Mechanis m of Action 19 As s es s ment by Route of Adminis tration 21 As s es s ment by Molecule Type 23 Melanocortin Receptor 4 (MC4-R or MC4R) - Companies Involved in Therapeutics Development 25 As traZ eneca Plc 25 Mallinckrodt Plc 26 Obexia AG 27 Palatin Technologies , Inc. 28 Pfizer Inc. 29 Retrophin Inc. 30 Rhythm Pharmaceuticals , Inc. 31 Melanocortin Receptor 4 (MC4-R or MC4R) - Drug Profiles 32 (liraglutide + s etmelanotide) - Drug Profile 32 Product Des cription 32 Mechanis m Of Action 32 R& D Progres s 32 bremelanotide - Drug Profile 33 Product Des cription 33 Mechanis m Of Action 33 R& D Progres s 33 corticotropin - Drug Profile 38 Product Des cription 38 Mechanis m Of Action 38 R& D Progres s 38 cos yntropin - Drug Profile 40 Product Des cription 40 Mechanis m Of Action 40 R& D Progres s 40 OBX-1201 - Drug Profile 41 Product Des cription 41 Mechanis m Of Action 41 R& D Progres s 41 PL-8905 - Drug Profile 42 Product Des cription 42 Mechanis m Of Action 42 R& D Progres s 42 Proteins to Agonize MC4R for Obes ity - Drug Profile 43 Product Des cription 43 Mechanis m Of Action 43 R& D Progres s 43 s etmelanotide - Drug Profile 44
Product Des cription 44 Mechanis m Of Action 44 R& D Progres s 44 Small Molecules to Agonize MC4-R for Obes ity - Drug Profile 47 Product Des cription 47 Mechanis m Of Action 47 R& D Progres s 47 Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile 48 Product Des cription 48 Mechanis m Of Action 48 R& D Progres s 48 Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dys function and Erectile Dys function - Drug Profile 49 Product Des cription 49 Mechanis m Of Action 49 R& D Progres s 49 Melanocortin Receptor 4 (MC4-R or MC4R) - Dormant Projects 50 Melanocortin Receptor 4 (MC4-R or MC4R) - Dis continued Products 52 Melanocortin Receptor 4 (MC4-R or MC4R) - Featured News & Pres s Releas es 53 Feb 26, 2016: Palatin Technologies Pres ents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 53 Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Us e of Bremelanotide for Female Sexual Dys function 53 Jan 07, 2016: Rhythm Receives FDA Breakthrough Therapy Des ignation for Setmelanotide for Treatment of POMC Deficiency Obes ity 54 Jan 07, 2016: Rhythm Receives Orphan Drug Des ignation for Setmelanotide for the Treatment of Prader-Willi Syndrome 54 Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phas e 3 Studies for Bremelanotide for Female Sexual Dys function 54 Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Dis eas e Activity in Patients with Pers is tently Active Sys temic Lupus Erythematos us 55 Nov 06, 2015: Rhythm Pres ents Cardiovas cular Safety Data from Phas e 1b/2a Clinical Trials of Setmelanotide in Obes ity 56 Nov 06, 2015: Rhythm Pres ents Pos itive Data from Phas e 1b Study of Setmelanotide for the Treatment of Genetic Obes ity 57 Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals ' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 58 Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals ' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 58 Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phas e 2 Study of Setmelanotide in Prader-Willi Syndrome 59 Aug 18, 2015: Palatin Technologies Supports FDA's Approval of the Firs t-Ever Treatment for Female Sexual Dys function 59 Jun 04, 2015: Rhythm Initiates Two Phas e 2 Clinical Trials of Setmelanotide in Rare Genetic Dis orders of Obes ity Caus ed by MC4 Pathway Deficiencies 60 Mar 27, 2015: Pos itive Outcomes With H.P. Acthar Gel In Proteinuria In Nephrotic Syndrome Reported At National Kidney Foundation Spring Congres s 61 Feb 20, 2015: Palatin Launches Reconnects tudy.Com In Support Of Bremelanotide Phas e 3 Program For Female Sexual Dys function 62 Appendix 64 Methodology 64 Coverage 64 Secondary Res earch 64 Primary Res earch 64 Expert Panel Validation 64 Contact Us 64 Dis claimer 65 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 Comparative Analys is by Unknown Stage Development, H1 2016 13 Number of Products under Development by Companies , H1 2016 14 Products under Development by Companies , H1 2016 15 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 16 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 17 As s es s ment by Monotherapy/Combination Products , H1 2016 18 Number of Products by Stage and Mechanis m of Action, H1 2016 20 Number of Products by Stage and Route of Adminis tration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Pipeline by As traZ eneca Plc, H1 2016 25 Pipeline by Mallinckrodt Plc, H1 2016 26 Pipeline by Obexia AG, H1 2016 27 Pipeline by Palatin Technologies , Inc., H1 2016 28 Pipeline by Pfizer Inc., H1 2016 29 Pipeline by Retrophin Inc., H1 2016 30
Pipeline by Rhythm Pharmaceuticals , Inc., H1 2016 31 Dormant Projects , H1 2016 50 Dormant Projects (Contd..1), H1 2016 51 Dis continued Products , H1 2016 52 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 18 Number of Products by Mechanis m of Actions , H1 2016 19 Number of Products by Stage and Mechanis m of Actions , H1 2016 19 Number of Products by Routes of Adminis tration, H1 2016 21 Number of Products by Stage and Routes of Adminis tration, H1 2016 21 Number of Products by Molecule Types , H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 23
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349